Detailed treatment for pneumonia
Reading File
Finding Sources
Finding Sources
Searching PubMed
"pneumonia" AND "treatment" AND "guidelines"
Reading File
Reading File
Reading File
Reading Article
PMID: 40679934
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks and a 2026 ATS guideline. Let me compile the detailed treatment guide.
Detailed Treatment of Pneumonia
Pneumonia treatment is organized around the site of acquisition (community vs. hospital/ventilator-associated), disease severity, and host immune status. Below is a structured breakdown.
1. Classification & Severity Assessment
Before initiating treatment, classify the patient using validated scoring systems:
- CURB-65 (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, Blood pressure <90 systolic or ≤60 diastolic, Age ≥65): score 0-1 = outpatient, 2 = inpatient, 3-5 = consider ICU
- Pneumonia Severity Index (PSI): Classes I-II = outpatient, III = brief inpatient/observation, IV-V = inpatient/ICU
- All patients should be assessed for oxygenation, comorbidities, and aspiration risk before selecting a regimen.
2. Community-Acquired Pneumonia (CAP)
Diagnostic Workup Before Treatment
- Sputum Gram stain + culture before antibiotics (for all hospitalized patients)
- Blood cultures x2 before antibiotic therapy
- Urinary antigen tests for S. pneumoniae and L. pneumophila in severe disease
- Nasopharyngeal PCR for influenza, SARS-CoV-2, respiratory viruses in selected cases
- Chest radiograph: confirms diagnosis (lobar consolidation, interstitial infiltrates, or cavitation)
- Bronchoscopy for immunocompromised patients or treatment failure
Key principle: Antibiotics should start within 4 hours of diagnosis - delays increase mortality. - The Washington Manual of Medical Therapeutics
2a. Outpatient CAP Treatment
| Patient Type | Regimen |
|---|---|
| No comorbidities, no MRSA/Pseudomonas risk | Amoxicillin 1000 mg PO q8h x5d, OR Doxycycline 100 mg PO q12h x5d, OR Azithromycin 500 mg day 1, then 250 mg days 2-5 |
| With comorbidities (COPD, DM, renal/cardiac/liver disease, alcoholism, malignancy, asplenia) | Amoxicillin-clavulanate 875/125 mg PO q12h OR Cefpodoxime 200 mg PO q12h OR Cefuroxime 500 mg PO q12h PLUS Doxycycline or Azithromycin |
| Comorbidities - monotherapy alternative | Respiratory fluoroquinolone: Levofloxacin 750 mg PO daily OR Moxifloxacin 400 mg PO daily |
Source: The Washington Manual of Medical Therapeutics, Table 14-9
2b. Inpatient CAP (Non-Severe)
- Beta-lactam + Macrolide: Ampicillin-sulbactam 1.5-3 g IV q6h (or Ceftriaxone 1-2 g IV daily, or Cefotaxime 1-2 g IV q8h, or Ceftaroline 600 mg IV q12h) PLUS Azithromycin
- OR Monotherapy: Respiratory fluoroquinolone (levofloxacin or moxifloxacin)
2c. Inpatient CAP (Severe/ICU)
- Beta-lactam PLUS macrolide (first-line combination)
- OR Beta-lactam PLUS fluoroquinolone
If prior respiratory isolation of MRSA: Add Vancomycin 15 mg/kg IV q12h (adjust for renal function and levels) OR Linezolid 600 mg IV/PO q12h
If prior respiratory isolation or high risk for P. aeruginosa: Add Piperacillin-tazobactam 4.5 g IV q6h, or Cefepime 2 g IV q8h, or Ceftazidime 2 g IV q8h, or Imipenem 500 mg IV q6h, or Meropenem 1 g IV q8h, or Aztreonam 2 g IV q8h
Note: Community-acquired MRSA is an important cause of severe, necrotizing pneumonia - always consider when appropriate. - Washington Manual
3. Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
Common Pathogens
- S. aureus (MRSA 15-20%), Klebsiella spp. (10%), Enterobacter spp. (5-10%), E. coli (5-10%), H. influenzae (5%), Acinetobacter (3%), Pseudomonas aeruginosa
- 20-25% of HAP may be caused by respiratory viruses alone (rhinovirus, influenza, parainfluenza, metapneumovirus)
General Principles
- Antibiotics can be withheld in clinically stable patients until diagnosis confirmed
- Immediate treatment is mandatory in rapidly deteriorating or hypotensive patients
- Tailor regimens to the patient's individual risk factors and local antimicrobial resistance profiles
Empiric HAP/VAP Treatment
Group A - Early onset HAP/VAP, no MDR risk factors:
- Monotherapy with agents targeting susceptible gram-negative rods (e.g., ceftriaxone, levofloxacin, moxifloxacin, ampicillin-sulbactam, or ertapenem)
Group B - MDR risk factors present (prior IV antibiotics in 90 days, ICU admission, prior MDR isolation):
- MRSA coverage: Linezolid or Vancomycin
- PLUS anti-Pseudomonal coverage (one or two agents from):
- Beta-lactams: Cefepime, Ceftazidime, Piperacillin-tazobactam, Imipenem, Meropenem
- Newer beta-lactam/beta-lactamase inhibitors: Imipenem-relebactam, Ceftolozane-tazobactam, Ceftazidime-avibactam
- Fluoroquinolones: Ciprofloxacin, Levofloxacin
- Others: Aztreonam, Colistin, Cefiderocol
De-escalation: If nasal PCR for MRSA is negative and local MRSA prevalence is <20%, MRSA coverage can be withheld. Narrow coverage once culture and sensitivity results are available. - Goldman-Cecil Medicine
4. Aspiration Pneumonia
- Often polymicrobial; oral anaerobes are a major contributor
- Antibiotics of choice: Amoxicillin-clavulanate, Clindamycin (anaerobic coverage), or Piperacillin-tazobactam
- Aspiration pneumonitis (chemical, non-infectious) does NOT require antibiotics - supportive care only
- Manage underlying risk factors (dysphagia, altered consciousness, GERD)
5. Pneumocystis Pneumonia (PCP) - Immunocompromised Hosts
- Agent: Pneumocystis jirovecii
- Drug of choice: Trimethoprim-sulfamethoxazole (TMP-SMX)
- Mild-moderate: TMP-SMX 15-20 mg/kg/day (TMP component) PO divided q6-8h x21 days
- Severe (PaO2 <70 mmHg or A-a gradient >35): Add adjunctive corticosteroids - Prednisone 40 mg PO BID days 1-5, then 40 mg daily days 6-10, then 20 mg daily days 11-21
- Alternatives: Pentamidine, Clindamycin + primaquine, Atovaquone (mild-moderate)
- Goldman-Cecil Medicine, Table 315
6. Immunocompromised Host Pneumonia
When no pathogen is identified, the radiographic pattern guides empiric therapy:
| Radiographic Pattern | Likely Pathogen | Empiric Therapy |
|---|---|---|
| Lobar consolidation | Bacterial (sometimes postobstructive) | Standard antibacterials |
| Interstitial pattern | Pneumocystis, viral, atypical bacteria | Broad-spectrum antibacterials + consider TMP-SMX for PCP |
| Nodular/cavitary | Bacteria, fungi, Nocardia | Broad-spectrum antibacterials + antifungal; consider Nocardia coverage |
- For serious fungal pathogens, consider antifungal agents targeting Cryptococcus, Aspergillus, or Mucorales species
- Always try to identify the specific pathogen via bronchoscopy/BAL, blood cultures, or tissue biopsy; expectorated sputum is unreliable
- Whenever possible, reduce immunosuppressive dosing to boost host immunity - Goldman-Cecil Medicine
7. Pediatric Pneumonia
Supportive Care (All Ages)
- Supplemental O2 to maintain SpO2 >90-92%
- Antipyretics (paracetamol/ibuprofen)
- Adequate hydration (oral, NG, or IV)
- Bronchodilators only if wheezing with known asthma
- Avoid cough suppressants in children (not effective, codeine discouraged due to respiratory depression risk)
- Honey is an evidence-based and safe cough remedy in children >1 year
Antibiotic Choice by Age/Pathogen
- Viral pneumonia (RSV, influenza, most cases <5 years): Supportive care ONLY - no antibiotics
- Bacterial (presumed): Amoxicillin is first-line for most outpatient bacterial pneumonia
- Life-threatening pneumonia complicating influenza: Vancomycin + an anti-Staphylococcal agent (covers CA-MRSA); de-escalate once cultures available
- Well-appearing febrile infants 28-90 days with confirmed RSV/bronchiolitis: low risk for bacterial co-infection - empiric antibiotics not required - Tintinalli's Emergency Medicine
8. Supportive & Adjunctive Therapy
| Intervention | Details |
|---|---|
| Oxygen therapy | Target SpO2 ≥94% (88-92% in COPD); high-flow nasal oxygen or NIV/CPAP for moderate-severe hypoxemia |
| Corticosteroids | 2026 ATS CAP Guideline recommends systemic corticosteroids for select severe CAP patients; established benefit in severe PCP; IV methylprednisolone or oral prednisone |
| IV fluids | Correct dehydration; monitor for fluid overload especially in elderly |
| Ventilatory support | NIV (BiPAP) for hypercapnic respiratory failure; mechanical ventilation for respiratory failure unresponsive to NIV |
| Physiotherapy | Chest physiotherapy and incentive spirometry to aid mucus clearance |
| Vaccination (prevention) | Pneumococcal vaccine (PCV13 + PPSV23) for age ≥65 and high-risk groups; influenza vaccine annually; COVID-19 vaccine |
9. Treatment Duration
- Outpatient CAP: Minimum 5 days; reassess at 5 days - continue only if not clinically stable
- Inpatient non-severe CAP: 5-7 days when response is good
- Severe or complicated CAP (including Legionella, Pseudomonas, MRSA): 7-14 days
- HAP/VAP: Studies support 8 days for most cases (equivalent outcomes to 15 days with less resistance risk)
- PCP: 21 days total
10. Treatment Failure / Non-Responding Pneumonia
Defined as failure to improve within 48-72 hours of appropriate therapy. Consider:
- Wrong pathogen - atypical, viral, fungal, TB, resistant organism
- Wrong antibiotic - inadequate coverage or dosing
- Complication - parapneumonic effusion, empyema, lung abscess, septic emboli
- Non-infectious mimics - pulmonary edema, PE, cryptogenic organizing pneumonia, vasculitis, drug reaction
- Immunosuppression - re-evaluate host immune status
Bronchoscopy with BAL, CT chest, and repeat cultures are warranted. Broaden coverage empirically while awaiting results. - Murray & Nadel's Textbook of Respiratory Medicine
Recent Guideline Update (2026)
The 2026 ATS Clinical Practice Guideline on CAP (PMID: 40679934) updated evidence-based recommendations on:
- Use of lung ultrasound for diagnosis (promising accuracy)
- Empiric antibacterial therapy when a respiratory virus test is positive (more nuanced approach)
- Antibiotic duration (shorter courses are supported by evidence)
- Role of systemic corticosteroids in select severe CAP patients
Sources: The Washington Manual of Medical Therapeutics (Table 14-9) | Goldman-Cecil Medicine | Tintinalli's Emergency Medicine | Murray & Nadel's Textbook of Respiratory Medicine | Fishman's Pulmonary Diseases and Disorders | ATS Practice Guideline 2026 (PMID: 40679934)
This is a shared conversation. Sign in to Orris to start your own chat.